Brian Gordon Feagan

Brian Gordon Feagan

Auto-generated profile, based on publicly available information

Brian Gordon Feagan

Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Lancet
Verified
Journal Article
Closed access
BFBrian G Feagan
Brian G Feagan
SDSilvio Danese
Silvio Danese
ELEdward V Loftus
Edward V Loftus
SVSéverine Vermeire
Séverine Vermeire
SSStefan Schreiber
Stefan Schreiber
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet

1 November 2015 in The Lancet
Verified
Journal Article
Closed access
RKReena Khanna
Reena Khanna
BBBrian Bressler
Brian Bressler
BLBarrett G Levesque
Barrett G Levesque
GZGuangyong Zou
Guangyong Zou
LSLarry W Stitt
Larry W Stitt
BFBrian G Feagan
Brian G Feagan

1 April 2017 in The Lancet
Verified
Journal Article
Closed access
BFBrian G Feagan
Brian G Feagan
WSWilliam J Sandborn
William J Sandborn
GDGeert D'HAens
Geert D'HAens
JPJulián Panés
Julián Panés
AKArthur Kaser
Arthur Kaser
WBWulf O Böcher
Wulf O Böcher

1 March 2014 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
BFBrian G. Feagan
Brian G. Feagan
JMJohn W.D. McDonald
John W.D. McDonald
RPRemo Panaccione
Remo Panaccione
RERobert A. Enns
Robert A. Enns
CBCharles N. Bernstein
Charles N. Bernstein
GGGordon R. Greenberg
Gordon R. Greenberg

21 October 2014 in Gut
Verified
Journal Article
Open access
NCNiels Vande Casteele
Niels Vande Casteele
RKReena Khanna
Reena Khanna
BLBarrett G Levesque
Barrett G Levesque
LSLarry Stitt
Larry Stitt
GZG Y Zou
G Y Zou
BFBrian G Feagan
Brian G Feagan
Objective: Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab. Design: In an observational study, 1487 trough serum samples from 483 patients with CD who participated in four clinical studies of maintenance infliximab therapy were analysed using a fluid phase mobility shift assay. Infliximab and ATI concentrations most discriminant for remission, defined as a C-reactive protein concentration of ≤5 mg/L, were determined by receiver operating characteristic curves. A multivariable regression model evaluated these factors as independent predictors of remission. Results: Based upon analysis of 1487 samples, 77.1% of patients had detectable and 22.9% had undetectable infliximab concentrations, of which 9.5% and 71.8%, respectively, were positive for ATI. An infliximab concentration of >2.79 μg/mL (area under the curve (AUC)=0.681; 95% CI 0.632 to 0.731) and ATI concentration of <3.15 U/mL (AUC=0.632; 95% CI 0.589 to 0.676) were associated with remission. Multivariable analysis showed that concentrations of both infliximab trough (OR 1.8; 95% CI 1.3 to 2.5; p<0.001) and ATI (OR 0.57; 95% CI 0.39 to 0.81; p=0.002) were independent predictors of remission. Conclusions: The development of ATI increases the probability of active disease even at low concentrations and in the presence of a therapeutic concentration of drug during infliximab maintenance therapy. Evaluation of strategies to prevent ATI formation, including therapeutic drug monitoring with selective infliximab dose intensification, is needed.

19 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
FRF. Rieder
F. Rieder
DBD. Bettenworth
D. Bettenworth
CMC. Ma
C. Ma
CPC. E. Parker
C. E. Parker
LWL. A. Williamson
L. A. Williamson
VJV. Jairath
V. Jairath